Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On May 17, 2024, CytomX Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation reflecting an amendment to increase the authorized number of shares of the Company’s common stock from 150,000,000 to 300,000,000 shares (the “Charter Amendment”). The Charter Amendment was approved by the Company’s stockholders at the Annual Meeting on May 15, 2024, as described below under Item 5.07.

A copy of the Amended and Restated Certificate of Incorporation reflecting the Charter Amendment is attached to this report as Exhibit 3.1.

Submission of Matters to a Vote of Security Holders.

The Company held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) on May 15, 2024. On March 19, 2024, the record date, there were 667,731,764 shares of the Company’s common stock outstanding, with each such share being entitled to one vote.

At the Annual Meeting, 46,918,673 shares of the Company’s common stock were voted online or by proxy for the four proposals set forth below, each of which is described in the Company’s Definitive Proxy Statement (the “Proxy Statement”) on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 4, 2024.

Proposal 1. The Company’s stockholders elected the Class III director nominees below to the Company’s Board of Directors to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or the earlier of their death, resignation or removal.

이거 3억개풀리면 좆되는거아님? 물려잇는데 지굼이라도 손절각?